NR3C2 and diabetic kidney disease: Several clinical studies reported the benefit of MR antagonists in diabetic kidney disease outcomes (Lindhardt et al., 2016; Sun et al., 2017; Wada et al., 2020) but clinical impact on non-diabetic CKD remains to be demonstrated.